A series of randomized, placebo-controlled n-of-1 trials (a randomized trial in individual patients) found no overall effect of atorvastatin 20 mg on muscle symptoms compared with placebo in participants who had previously reported severe muscle symptoms when taking statins. A total of 200 participants who had recently stopped or were considering stopping treatment with statins because of muscle symptoms were randomized to a sequence of 6 double blinded treatment periods (two months each) of atorvastatin 20 mg daily or placebo. 151 participants provided symptoms scores for at least one statin period and one placebo period and were included in the primary analysis. Overall, no difference in muscle symptom scores was found between the statin and placebo periods. Withdrawals because of intolerable muscle symptoms were 18 participants (9%) during a statin period and 13 (7%) during a placebo period. Two thirds of those completing the trial reported restarting long-term treatment with statins. The findings are in line with previous and concurrent studies and suggest a nocebo effect since most patients taking statins did not experience symptoms causally related to their statin. However, a causal link between statins and rare risk of myopathy, even severe rhabdomyolysis is well characterized. Source: https://www.bmj.com/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.